ClinicalTrials.gg
Active, not recruitingNCT05692596Updated Sep 15, 2026

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

An observational study in Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst and Chronic Pancreatitis, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
317
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Pancreatic Cyst with a site in United States — 20 open to participants now, 23 under way, 1 of them phase 3. Pancreatic Cyst · United States.

Planned enrollment
14th of 32
317 · median 300
Started
2022
with 1 other
Observational
32 of 54
12 open now
Primary completion
2027-07
later than 9 of 22 live
Registered
44th of 54
by date
Lead sponsor
2 of 54
H. Lee Moffitt Cancer Center and Research Institute

Among the 54 studies in Pancreatic Cyst with a site in United States, this one is the 14th largest by planned enrollment of the 32 observational ones that give a count, is one of 2 that started in 2022, is one of 32 observational ones, reaches primary completion later than 9 of the 22 other live ones, and was the 44th registered.

Pancreatic Cyst

97 studies on the registry are indexed under Pancreatic Cyst; 37 are open to participants now.

Browse Pancreatic Cyst studies →

Open to participants now

20 of the 54 studies in Pancreatic Cyst with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Pancreatic Cyst studies recruiting now, 25 (76%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Pancreatic Cyst with a site in United States, or all of them as a file.
02

Study summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cyst
  • Chronic Pancreatitis
  • Fatty Pancreas
  • Genetic Pancreatic Cancer
  • Genetic Pancreatitis
  • BRCA Mutation
  • Lynch Syndrome
  • FAP
  • Familial Atypical Multiple Mole-Melanoma
  • PALB2 Gene Mutation
  • Peutz-Jeghers Syndrome
  • Ataxia Telangiectasia

Keywords

  • pancreas
  • database
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients presenting at the Moffitt GI clinic

Eligibility criteria

Inclusion Criteria:

  • 18 years of age or older
  • Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
  • Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
  • Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
317 participants (estimated)
Patient registry
No

Groups and cohorts

  • All participants

    Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.

    Other: Data collection

Interventions

  • OtherData collection

    Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

06

What researchers measure

Primary outcomes

  1. Database creation

    A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jul 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 20, 2023
StartActual
Oct 6, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05692596
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Oct 6, 2022
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Shaffer Mok, MD, MBS
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion